Please login to the form below

Not currently logged in
Email:
Password:

AZ discontinues asthma medicine

AstraZeneca is to discontinue production of an inhaled version of its asthma medication Pulmicort due to 'manufacturing issues'

AstraZeneca (AZ) is to discontinue production of the pressurised metered dose inhaler (pMDI) version of its asthma medication Pulmicort (budesonide), in both its 100µg and 200µg doses, due to 'manufacturing issues'.

The company said the problem is due to 'product-specific processes and components', the combination of which was used solely in the manufacturing of Pulmicort pMDI.

The decision to discontinue the product was not related to the active ingredient of the medicine, budesonide - a corticosteroid also used in AZ's nasal inhalant, Rhinocort, for conditions such as hayfever, and the controlled-release capsule Entocort for Crohn's disease.

Other unaffected products include AZ's Pulmicort Turbuhaler, Pulmicort Respules and Pulmicort Flexhaler.

David Smith, executive vice president, Global Operations and IS, AstraZeneca, said the company had "exhausted all potential solutions" in its efforts to solve the technical problems and to continue supplying the product.

"[I]t is in the patient's best interest to find an alternative medication as soon as possible," continued Smith, with AZ stating that it is working with regulatory authorities and healthcare professionals to help patients on Pulmicort pMDI to switch treatments.

Patients currently on the medication will be able to finish any current supplies they have remaining.

7th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics